Project Term: 2015-2020
Budget: NT$5 million
Origin: The Tang Prize is awarded on a biennial basis, each with a cash reward of NT$40 million. Projects proposed by the laureates also receive a grant of up to NT$10 million. The 2014 grant for Biopharmaceutical Science is shared between Dr. Allison and Prof. Honjo.
Project summary: "Improvement of PD-1 antibody cancer immunotherapy" will continue the work that won Prof. Honjo the prize in Biopharmaceutical Science in 2014. Dr. Tausku Honjo, recipient of the inaugural Tang Prize in Biopharmaceutical Science, decided to dedicate his grand funds to the launch of “Improvement of PD-1 (Programmed Death Cell Protein-1) Antibody Cancer Immunotherapy,” a cancer-fighting research project. PD-1 Antibody Immunotherapy has proven to be more effective than any other immunotherapy treatment developed over the past 30 years. The project has not only created a new research field related to PD-1 biology, but also established the basic principles of anti-PD-1 and anti-PD-L1 antibody treatments for tumor growth.
Press Release: Laureate Tasuku Honjo Moves Forward with Immunotherapy Cancer Research
Related link: http://www2.mfour.med.kyoto-u.ac.jp/en/index.html
Final Report: https://reurl.cc/OVjnjv